Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB208
- Development stage
- Unknown
- Lead developer
- Ligand Pharmaceuticals
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
SB208 is a topical nitric oxide-releasing gel developed by Novan, Inc. (now a part of Ligand Pharmaceuticals) for the treatment of superficial cutaneous fungal infections, specifically interdigital tinea pedis and onychomycosis. The therapeutic utilizes Novan's proprietary Nitricil technology, which employs berdazimer sodium as a nitric oxide-storing macromolecule. The drug is supplied as a two-component system consisting of berdazimer sodium and a hydrogel that are admixed immediately prior to application. This reaction triggers the controlled release of nitric oxide, which provides broad-spectrum antifungal activity against dermatophytes such as *Trichophyton rubrum* by disrupting fungal cell processes. SB208 has demonstrated efficacy and safety in Phase 2 clinical trials for tinea pedis.
- Other names
- berdazimer sodium gel
Beyond the preview
Go deeper on SB208.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB208.